Minerva Neurosciences (NASDAQ: NERV) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, analyst recommendations, earnings and risk.
This is a summary of recent ratings and target prices for Minerva Neurosciences and Ionis Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Insider and Institutional Ownership
70.5% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 91.1% of Ionis Pharmaceuticals shares are held by institutional investors. 9.6% of Minerva Neurosciences shares are held by company insiders. Comparatively, 2.4% of Ionis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This table compares Minerva Neurosciences and Ionis Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Minerva Neurosciences and Ionis Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Minerva Neurosciences||N/A||N/A||-$31.52 million||($1.08)||-8.24|
|Ionis Pharmaceuticals||$507.67 million||10.74||-$5.96 million||$0.08||542.88|
Ionis Pharmaceuticals has higher revenue and earnings than Minerva Neurosciences. Minerva Neurosciences is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Minerva Neurosciences has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 2.48, meaning that its stock price is 148% more volatile than the S&P 500.
Ionis Pharmaceuticals beats Minerva Neurosciences on 9 of the 13 factors compared between the two stocks.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia. It also offers MIN-117, a compound that has completed Phase IIa clinical trial for the treatment of patients suffering from major depressive disorder (MDD); and seltorexant, which is in Phase IIb clinical trial for treating insomnia and MDD. The company' preclinical stage product is MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the MIN-117 compound and roluperidone worlwide, excluding Asia; and co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of seltorexant. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein. It is also developing inotersen, an antisense drug Ionis to treat patients with hereditary transthyretin amyloidosis; and volanesorsen, an antisense drug for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy. In addition, the company is developing drugs for various indications, such as cardiometabolic diseases caused by lipid disorders; cardiovascular disease, clotting disorders, and Alzheimer's and Parkinson's diseases; and acromegaly, amyotrophic lateral sclerosis, beta-thalassemia, and Huntington's disease. Ionis Pharmaceuticals, Inc. has a collaboration agreement with AstraZeneca to discover and develop antisense therapies for treating cardiovascular and metabolic diseases, and cancer; and Biogen Inc. to develop and commercialize therapies for neurological disorders, SMA, and neurodegenerative diseases. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.